How Long Does Jeuveau Last? Day 30 Endpoint, 20 Units, and Why 40 Units Is Not Approved

When patients and healthcare providers research Jeuveau (prabotulinumtoxinA-xvfs, BLA 761085, manufactured by Daewoong Pharmaceutical and marketed in the United States by Evolus, Inc.), aesthetic marketing campaigns and medical spa websites routinely present a familiar summary: "Jeuveau is a modern, state-of-the-art alternative to Botox that kicks in rapidly and lasts 3 to 4 months." In recent years, commercial marketing has expanded that messaging even further, with select med spa blogs promoting an "extra-strength, long-lasting 6-month Jeuveau protocol."

The evidence-based clinical reality is substantially more rigorous: the official United States Prescribing Information (US PI) approved by the FDA contains no labeled duration sentence stating that the clinical effect lasts 3 to 4 months. The FDA label establishes a Day 30 primary efficacy endpoint, an approved 20-Unit glabellar dose, and a mandatory 3-month retreatment floor. Claims of 5- to 6-month longevity stem entirely from an investigational, off-label 40-Unit Phase 2 clinical trial.

To understand how long Jeuveau actually lasts—and how its molecular biology, clinical pharmacology, and regulatory trial endpoints compare against Botox Cosmetic, Dysport, Xeomin, Daxxify, and Letybo—one must analyze the pivotal Phase 3 registration studies (EV-001 and EV-002), the 150-day time-course published by Beer et al. (2019), and the 40-Unit dose-escalation pilot published by Fagien et al. (2024). For head-to-head brand evaluations, explore our comprehensive guide to Jeuveau vs. Botox; for unit pricing and national cost dynamics, see our reference on Botox and neurotoxin pricing per unit.

                     [Jeuveau Regulatory & Dosing Profile]

  Biologics License Application: BLA 761085 (Evolus, Inc. / Daewoong Pharmaceutical)
  FDA Approval Timeline:         ORIG Approval: 2019-02-01 | SUPPL 1 (Labeling): 2019-07-12
  Proper Nonproprietary Name:    PrabotulinumtoxinA-xvfs (100 Units Lyophilized Powder)
  Molecular Complex Weight:      900 kDa Botulinum Toxin Type A Complex (150 kDa Active Neurotoxin Core)
  Labeled Aesthetic Indication:  Temporary improvement in moderate to severe glabellar lines in adults
  Approved Glabellar Dose:       20 Units total (0.1 mL / 4 Units across 5 anatomical injection sites)
  Labeled Retreatment Floor:     "No more frequently than every 3 months" (Section 2.3)
  Labeled Duration Statement:    None in US PI (Evaluates Day 30 composite investigator + subject success)
  Pivotal Day 30 Success Rates:  EV-001: 67% vs. 1% Placebo | EV-002: 71% vs. 1% Placebo
  Off-Label 40-Unit Status:      Fagien 2024 Phase 2: Median 183 Days (~26 Weeks); NOT FDA-Approved

---

Direct Answer: Does the Jeuveau Label Say 3 to 4 Months?

When evaluating the duration of Jeuveau from a regulatory, pharmacological, and real-world clinical perspective:

• What the FDA package insert explicitly states: Jeuveau is approved strictly for the temporary improvement in the appearance of moderate to severe glabellar lines (vertical frown lines between the eyebrows) in adult patients. The FDA-approved dose is exactly 20 Units administered as five equal 4-Unit (0.1 mL) intramuscular injections into the procerus and paired corrugator supercilii muscles. Section 2.3 of the Prescribing Information explicitly mandates that "JEUVEAU should be administered no more frequently than every 3 months."
• The missing duration sentence: Unlike Dysport's FDA label (which explicitly states "the clinical effect may last up to 4 months") or Daxxify's FDA label (which explicitly states a "median duration of 6 months (24 weeks)"), the Jeuveau package insert does not contain a summary duration statement. It evaluates and establishes efficacy at a single primary regulatory timepoint: Day 30.
• Real-world clinical persistence: In routine aesthetic practice at the labeled 20-Unit dose, patients generally observe initial muscle softening over several days, reach peak effect by the labeled Day 30 visit, and experience a gradual return of dynamic movement before the next allowed treatment. Open-label EV-004 and EV-006 enrolled 922 subjects at 20 Units up to a maximum total of 80 Units, with a median of three treatments in one year—a visit rhythm consistent with the 3-month retreatment floor, not a PI duration sentence.
• The source of 6-month marketing: Advertisements claiming that Jeuveau lasts 5 to 6 months derive from an investigational Phase 2 dose-escalation pilot study (Fagien et al., 2024) evaluating an unapproved 40-Unit dose (double the standard FDA-cleared amount).
• Off-label treatment areas: Jeuveau is not approved by the FDA for horizontal forehead lines or lateral canthal lines (crow's feet). Administering Jeuveau into the frontalis or orbicularis oculi muscles is an off-label clinical practice that exhibits distinct dosing requirements, safety considerations, and duration patterns. See our clinical guide on forehead Botox units and approved toxins.

---

Molecular Biology: What Is PrabotulinumtoxinA-xvfs?

To understand how Jeuveau functions and why its clinical effects eventually subside, one must examine its biochemical structure and cellular pharmacology:

                    [PrabotulinumtoxinA-xvfs Molecular Architecture]

  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ 900 kDa Clostridial Complex (Stabilized by Hemagglutinin & NTNH Proteins)   │
  │                                                                             │
  │   ┌─────────────────────────────────────────────────────────────────────┐   │
  │   │ 150 kDa Active Neurotoxin Core                                      │   │
  │   │                                                                     │   │
  │   │   ┌──────────────────────────────┐   ┌──────────────────────────┐   │   │
  │   │   │ 100 kDa Heavy Chain (HC)     │───│ 50 kDa Light Chain (LC)  │   │   │
  │   │   │ Presynaptic Neuronal Binding │ S │ Zinc Endopeptidase       │   │   │
  │   │   │ & Cellular Internalization   │─S─│ Cleaves SNAP-25 Protein  │   │   │
  │   │   └──────────────────────────────┘   └──────────────────────────┘   │   │
  │   └─────────────────────────────────────────────────────────────────────┘   │
  └─────────────────────────────────────────────────────────────────────────────┘

1. The 900 kDa Complex and Hi-Pure Purification

PrabotulinumtoxinA-xvfs is produced by fermentation of Clostridium botulinum type A (Hall strain). Like onabotulinumtoxinA (Botox), Jeuveau is formulated as a 900 kDa macromolecular complex consisting of the 150 kDa core neurotoxin surrounded by non-toxic non-hemagglutinin (NTNH) and hemagglutinin (HA) auxiliary proteins.

Daewoong utilizes a proprietary purification process known as "Hi-Pure technology," which incorporates two crystallization stages followed by series chromatography to isolate the 900 kDa complex with high purity and minimize inactive toxoid content.

2. Complex Dissociation at Physiologic pH

When Jeuveau is injected, the 900 kDa complexing proteins are not a months-long depot. The PI mechanism is cleavage of SNAP-25 and reduced acetylcholine release; auxiliary proteins are not a labeled duration extender.

3. Presynaptic Blockade Mechanism of Action

The 150 kDa neurotoxin consists of a 100 kDa heavy chain and a 50 kDa light chain joined by a single disulfide bond:

1. Targeted Binding: The carboxy-terminal domain of the 100 kDa heavy chain binds with high affinity to polysialogangliosides and synaptic vesicle glycoprotein 2 (SV2) receptors on the presynaptic cholinergic nerve terminal.
2. Receptor-Mediated Endocytosis: The toxin-receptor complex is internalized into an endocytic vesicle within the nerve terminal.
3. Endosomal Translocation: Acidification of the endosome triggers a conformational change in the amino-terminal domain of the heavy chain, forming a pore that translocates the 50 kDa catalytic light chain into the neuronal cytosol. The disulfide bond is cleaved by intracellular thioredoxin reductase.
4. Enzymatic Cleavage of SNAP-25: The 50 kDa light chain is a zinc-dependent endopeptidase that specifically cleaves SNAP-25 (synaptosomal-associated protein 25 kDa) between amino acids Gln197 and Arg198.
5. Inhibition of Exocytosis: Cleaved SNAP-25 cannot form the functional SNARE complex (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) required for acetylcholine vesicle fusion. Acetylcholine release into the neuromuscular junction is halted, resulting in flaccid chemical denervation and muscle relaxation.

                    [Presynaptic Neuromuscular Blockade Cycle]

  [Stage 1: Binding]         Heavy chain (100 kDa) binds SV2 receptors & polysialogangliosides
           │
           ▼
  [Stage 2: Internalization] Receptor-mediated endocytosis into presynaptic vesicle
           │
           ▼
  [Stage 3: Translocation]   Light chain (50 kDa zinc endopeptidase) enters the neuronal cytosol
           │
           ▼
  [Stage 4: SNAP-25 Cleave]  Light chain cleaves SNAP-25 at Gln197-Arg198 bond ──► Blocks ACh Release
           │
           ▼ (Peak assessment: labeled Day 30 visit)
  [Stage 5: Axonal Sprout]   PI: axonal sprouting may occur as the muscle is denervated
           │
           ▼ (Return of movement: not a labeled calendar)
  [Stage 6: Synaptic Return] PI: reinnervation may slowly reverse the denervation

---

Why Neuromuscular Blockade Wears Off (The Recovery Process)

The Jeuveau PI states that when injected intramuscularly, the product produces partial chemical denervation; the muscle may atrophy, axonal sprouting may occur, and extrajunctional acetylcholine receptors may develop, and that reinnervation may slowly reverse the denervation. That is the labeled recovery sketch. It is not a week-by-week calendar, and it is not a duration sentence.

Clinic 3-to-4-month retreatment is consistent with EV-004/EV-006 (median three treatments in one year) and with the 3-month floor. That practice pattern is not a substitute for a PI sentence that "clinical effect may last up to 3 to 4 months."

---

Direct Comparison: FDA Labels Across the 6 US Neurotoxins

To understand how Jeuveau fits into the broader neuromodulator landscape, we must examine the exact regulatory wording across all six FDA-approved botulinum toxin type A package inserts:

(Correction note: The comparison table in our Dysport duration guide previously categorized Jeuveau as possessing a labeled duration of "up to 3 to 4 months." As documented here, while clinical practice follows a 3-to-4-month retreatment rhythm, the Jeuveau Prescribing Information does not contain an explicit duration claim).

---

Pivotal Trial Data: What EV-001 and EV-002 Measured

Jeuveau received FDA approval based on two identical multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trials: EV-001 and EV-002.

                 [EV-001 and EV-002 Trial Structure]

  Study Design:        Randomized, Double-Blind, Multi-Center, Placebo-Controlled (3:1 Active-to-Control)
  Trial Population:    Adults aged 18 to 65 with moderate (Grade 2) or severe (Grade 3) glabellar lines
  Primary Endpoint:    Composite ≥2-Grade Improvement on the 4-Point Glabellar Line Scale (GLS)
                       at Maximum Frown at Day 30, Assessed Independently by Investigator and Patient.
  Enrollment Totals:   EV-001 (N=330: 246 Jeuveau, 84 Placebo) | EV-002 (N=324: 246 Jeuveau, 78 Placebo)

           [Primary Efficacy Responder Rates at Day 30 (Table 3)]

  Trial / Data Source            Jeuveau 20 Units       Placebo Arm          p-value
  ────────────────────────────   ────────────────────   ──────────────────   ───────────
  EV-001 (s001 PI PDF Table 3)   67% (N=246)            1% (N=84)            p < 0.001
  EV-001 (DailyMed HTML SPL)     68% (N=246)            1% (N=84)            p < 0.001
  EV-001 (Beer 2019 ITT Paper)   67.5% (166/246)        1.2% (1/84)          p < 0.001
  EV-002 (s001 PI PDF Table 3)   71% (N=246)            1% (N=78)            p < 0.001
  EV-002 (DailyMed HTML SPL)     70% (N=246)            1% (N=78)            p < 0.001
  EV-002 (Beer 2019 ITT Paper)   70.4% (173/246)        1.3% (1/78)          p < 0.001

1. Understanding the Composite 2-Grade Endpoint

The FDA requires a rigorous "composite" efficacy standard for aesthetic neurotoxin approval:

• The 4-Point Glabellar Line Scale (GLS): Lines at maximum frown are graded as 0 (None), 1 (Mild), 2 (Moderate), or 3 (Severe).
• The ≥2-Grade Requirement: To be counted as a responder, a subject entering the trial with Severe lines (Grade 3) had to improve to Mild (Grade 1) or None (Grade 0). A subject entering with Moderate lines (Grade 2) had to reach completely smooth skin (Grade 0).
• Independent Dual Concurrence: The subject was only classified as a treatment success if both the blinded investigator and the patient independently rated the outcome as a ≥2-grade improvement. If the physician rated a 2-grade improvement but the patient rated a 1-grade improvement, the subject was categorized as a treatment failure.

2. Investigator-alone and subject-alone ≥2-grade scores, and GAIS

Beer 2019 also reports the non-composite ≥2-grade rates at Day 30 (investigator and subject scored separately): absolute differences versus placebo were 76.3% and 73.1% in EV-001 and 79.8% and 72.3% in EV-002. Those are still ≥2-grade GLS scores, not a milder ≥1-grade endpoint. On the Global Aesthetic Improvement Scale, more than 90% of prabotulinumtoxinA subjects were rated "improved" or "much improved" by both investigator and subject at the Day 7, 14, and 30 visits. Do not upgrade GAIS "improved" into a labeled duration or into a 91% ≥1-grade GLS table.

---

The Time-Course of Fade: What Happens at Day 90, 120, and 150?

While the FDA Prescribing Information does not tabulate efficacy visits beyond Day 30, the peer-reviewed clinical trial publication by Beer et al. (2019) tracked composite responder rates across the full 150-day post-injection study period:

          [Jeuveau vs. Placebo Composite Absolute Differences Over Time]

  Post-Injection Visit   EV-001 Absolute Difference (J - P)   EV-002 Absolute Difference (J - P)
  ────────────────────   ──────────────────────────────────   ──────────────────────────────────
  Day 30 (Peak Success)  66.3% (p < 0.001)                    69.1% (p < 0.001)
  Day 90 (Month 3)       25.2% (p < 0.001)                    25.8% (p < 0.001)
  Day 120 (Month 4)       7.0% (p = 0.024)                    12.4% (p = 0.001)
  Day 150 (Month 5)       4.6% (p = 0.048)                     4.6% (p = 0.048)

                     [Jeuveau 150-Day Efficacy Fade Curve]

  100% ┼───────────────────────────────────────────────────────────
   80% ┼           ● Day 30 Peak (~68% Composite Responder Rate)
   60% ┼            ╲
   40% ┼             ╲
   20% ┼              ● Day 90 (~25% Absolute Difference vs. Placebo)
    0% ┼───────────────────────● Day 120 (7–12%)────● Day 150 (4.6%)──
       0          30          60          90          120         150 Days

Clinical Interpretation of the Time-Course Data:

1. The Day 90 gap is an absolute difference, not a treated-arm success rate. Beer reports composite absolute differences of 25.2% (EV-001) and 25.8% (EV-002) at Day 90, still statistically significant. Those are treated-minus-placebo gaps. This page will not invent a Day 90 treated-arm percent from those differences.
2. The tail at Day 120–150 is small. Absolute differences fall to 7.0% and 12.4% at Day 120 and 4.6% in both trials at Day 150. Statistical significance at 4.6% is not a 5-month duration claim for the average patient.
3. Do not mix DailyMed HTML 68%/70%, the 2019 PDF 67%/71%, and Beer ITT 67.5%/70.4%. Same EV-001/EV-002 trials; rounding and ITT versus the labeled whole-number table.
4. GAIS and satisfaction last longer than the composite ≥2-grade gap. At Day 150 or early termination, Beer reports investigator/subject GAIS "improved or much improved" of 53.6% / 50.2% in EV-001 and 43.0% / 57.0% in EV-002, and 70.0% / 71.3% of Jeuveau subjects still "satisfied" or "very satisfied." A 4.6% composite absolute difference and a ~70% satisfaction tail are different endpoints. Neither is a labeled duration sentence. For on-label Botox and Xeomin duration language, see how long Botox lasts and how long Xeomin lasts.

---

The 40-Unit "Extra Strength" Study: Fagien 2024 Phase 2 Data

Med spa advertisements promoting a "6-month Jeuveau treatment" rely on an exploratory Phase 2 randomized, active-controlled clinical trial published in the Aesthetic Surgery Journal (Fagien et al., 2024;44(9):987–1000, PMC11334208; ClinicalTrials.gov identifier NCT05320393):

                   [Fagien 2024 Table 2 — median days to return to baseline GLS]

  Treatment Arm (Glabellar Dose)     Arm Size    Investigator median (all patients)
  ────────────────────────────────   ────────    ──────────────────────────────────────────────
  PrabotulinumtoxinA-xvfs 40 Units   n = 51      183 days (95% CI 153–211)
  PrabotulinumtoxinA-xvfs 20 Units   n = 51      149 days (95% CI 130–174)
  OnabotulinumtoxinA 20 Units        n = 50      148 days (95% CI 121–174)

           [Fagien 2024 Median Duration by Glabellar Dose]

  40U Jeuveau:  [==============================================] 183 Days (~26.1 Weeks)
  20U Jeuveau:  [====================================] 149 Days (~21.3 Weeks)
  20U Botox:    [====================================] 148 Days (~21.1 Weeks)
                0     30     60     90    120    150    180 Days

Critical Clinical Analysis of the 40-Unit Findings:

1. Unlabeled Regimen: Administering 40 Units of Jeuveau into the glabella is twice the FDA-approved dose. It is an investigational, off-label protocol that has not received FDA approval for extended duration.
2. 20-Unit Equivalence: At the approved 20-Unit dose, Jeuveau (149 days) and Botox Cosmetic (148 days) demonstrated virtually identical median durations in this trial.
3. The Daxxify Comparison: Daxxify is specifically formulated with an anchoring peptide (RTP004) and is FDA-approved at a 40-Unit dose with a labeled median duration of 6 months (24 weeks). For patients seeking a formally approved 6-month duration, see our guide on how long Daxxify lasts.
4. Safety Tradeoffs of Dose Escalation: Doubling the injected neurotoxin volume in the glabella increases the hydrostatic pressure during injection and raises the risk of toxin diffusion into the levator palpebrae superioris muscle, potentially causing eyelid ptosis (drooping).

---

Safety Profile, Adverse Events, and Immunogenicity

In the combined safety population of pivotal trials EV-001 and EV-002 (N=492 Jeuveau-treated subjects vs. N=162 placebo subjects), PI Table 2 reports adverse reactions at higher frequency (≥1%) in the Jeuveau group:

1. Eyelid Ptosis Incidence

Eyelid ptosis occurred in 2% of subjects (8 out of 492) receiving 20 Units of Jeuveau. In all cases, ptosis was temporary and resolved spontaneously as the toxin diffused out of the neuromuscular junction over several weeks.

2. Long-Term Repeat Dosing (EV-004 & EV-006)

In open-label, long-term safety studies, 922 subjects received up to 80 Units of Jeuveau over a 12-month period, receiving a median of three treatments per year. The adverse event profile did not increase with repeated administrations.

3. Immunogenicity (section 6.2)

Among 1,414 subjects treated with prabotulinumtoxinA-xvfs, 2 had pre-existing antibodies and 2 had treatment-emergent antibodies. The PI discusses neutralizing antibodies as an assay issue and as a theoretical cause of later nonresponse. It does not publish a "zero neutralizing antibodies" count. Do not upgrade 2 + 2 binding-antibody rows into a claim that secondary nonresponse cannot occur.

---

Reconstitution, Dilution, and Handling

The physical handling and dilution of Jeuveau directly impact delivered potency and spatial control:

• Vial Presentation: Jeuveau is supplied in single-dose glass vials containing 100 Units of vacuum-dried prabotulinumtoxinA-xvfs.
• Reconstitution Fluid: Must be reconstituted exclusively with sterile, preservative-free 0.9% Sodium Chloride Injection, USP.
• Standard glabellar dilution (labeled Table 1): Adding 2.5 mL of preservative-free 0.9% Sodium Chloride Injection, USP, to a 100-Unit vial yields 4 Units per 0.1 mL. The labeled 20-Unit dose is five 0.1 mL intramuscular injections into the mapped glabellar sites. That is the Prescribing Information, not a universal dose for other muscles. Follow the current label and the injector.
• Storage and Stability: Unopened vials must be refrigerated at 2°C to 8°C (36°F to 46°F). Once reconstituted, the solution must be stored in a refrigerator (2°C to 8°C) and administered within 24 hours (Section 2.2). The PI also requires that reconstituted Jeuveau be used for only one injection session and only one patient.

---

Indication Boundaries: Why Forehead Jeuveau Is Off-Label

The US Prescribing Information includes a clear regulatory boundary:

"JEUVEAU is not approved for the treatment of spasticity or any conditions other than glabellar lines."

                 [Approved vs. Off-Label Treatment Areas for Jeuveau]

  Anatomical Area     FDA Regulatory Status   Standard Dosing Context & Considerations
  ─────────────────   ─────────────────────   ────────────────────────────────────────────────
  Glabellar Lines     FDA-APPROVED (20 U)     On-label; five 4-Unit sites; 3-month floor
  Forehead Lines      OFF-LABEL               Requires frontalis assessment to avoid brow drop
  Crow's Feet         OFF-LABEL               Lateral orbicularis oculi; off-label use
  Masseter / Jawline  OFF-LABEL               Off-label muscle relaxation; see masseter guides
  Lip Flip (Perioral) OFF-LABEL               Micro-dosing; rapid movement shortens duration

When injectors treat forehead lines or crow's feet with Jeuveau, they are exercising clinical off-label judgment. Because the frontalis muscle is the sole elevator of the eyebrows, injecting off-label forehead patterns requires lower, diffuse dosing to prevent heavy, descended brows. Duration in the forehead is frequently shorter (2 to 3 months) due to constant dynamic facial expression.

---

Clinical Troubleshooting: What to Ask When Jeuveau Wears Off Early

If you feel that your Jeuveau treatment lost effectiveness prematurely, review these clinical considerations before seeking an immediate retreatment:

1. Was the result complete at the Day 30 labeled visit? The PI primary endpoint is Day 30. Early movement at two weeks can be incomplete onset, incomplete 20-Unit delivery, or placement—not proof the product "doesn't last."
2. Are you past the 3-month floor? Beer still shows a statistically significant composite gap at Day 90, then a small tail at Day 120–150. Faint movement before the next allowed visit is expected biology, not a manufacturing defect.
3. Was the treated area off-label? Forehead and crow's feet are not Jeuveau indications. Duration data in the PI are glabellar.
4. Was retreatment sooner than 3 months? The label forbids that floor. Antibody risk is a labeled theoretical concern for botulinum toxins generally; it is not a reason to invent a neutralizing-antibody rate.

---

Questions to Ask Your Injector About Jeuveau Longevity

1. "Are you administering the full 20 Units across the 5 standard FDA-labeled glabellar injection points?"
   Why to ask: Prevents partial dosing or dilution errors that cause early fade.
2. "What dilution volume are you using (e.g., 2.5 mL of preservative-free saline per 100-Unit vial)?"
   Why to ask: Confirms accurate concentration (4 Units per 0.1 mL) and precise aliquot delivery.
3. "If I am looking for a treatment that lasts 5 to 6 months, should I consider Daxxify or an off-label dose?"
   Why to ask: Clarifies whether the provider is adhering to labeled dosing or recommending an investigational 40-Unit protocol.
4. "Do you recommend waiting the full 14 to 30 days before evaluating symmetry and final muscle relaxation?"
   Why to ask: Aligns expectations with the biological timeline of presynaptic SNARE complex blockade.

---

Frequently Asked Questions

How long does Jeuveau last compared to Botox?

At the labeled 20-Unit glabellar dose, Fagien 2024 found nearly identical investigator medians (149 vs 148 days). Neither brand's US PI claims superiority. Jeuveau's PI has no "lasts 3 to 4 months" sentence; BOTOX Cosmetic's duration language lives on its own label. Clinic 3-to-4-month schedules follow the retreatment floor and open-label visit rhythm.

Is 20 units of Jeuveau a lot?

No. 20 Units is the exact FDA-approved dose for treating moderate to severe frown lines between the eyebrows, divided into five 4-Unit injections.

Does Jeuveau last 6 months?

Not at the approved dose. Marketing claims of 6-month duration stem from an off-label Phase 2 clinical trial (Fagien et al., 2024) that evaluated an unapproved 40-Unit dose (double the standard amount).

Is extra-strength Jeuveau FDA-approved?

No. Administering 40 Units of Jeuveau in the glabella is an investigational, off-label protocol. Daxxify remains the only FDA-approved neuromodulator labeled for a 6-month median duration at its approved 40-Unit dose.

How often can you get Jeuveau?

According to the FDA Prescribing Information, Jeuveau should be administered no more frequently than every 3 months. Injecting sooner than 90 days is discouraged to prevent adverse effects and minimize the risk of antibody development.

Why is my Jeuveau not working?

Assess whether you are evaluating the result before Day 14 (full synaptic blockade takes two weeks), whether you received the full 20 Units, or whether dynamic movement is naturally returning around Month 3 (the expected biological timeline).

---

Sources

• U.S. Food and Drug Administration / DailyMed: JEUVEAU (prabotulinumtoxinA-xvfs) Prescribing Information, BLA 761085, Set ID 17a914c1-e54b-4b50-965d-b0fd9111bba4 (Revised July 2019): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17a914c1-e54b-4b50-965d-b0fd9111bba4
• U.S. Food and Drug Administration, Center for Drug Evaluation and Research: BLA 761085 Labeling Approval (761085s001lbl.pdf, Approved July 12, 2019): https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761085s001lbl.pdf
• U.S. Food and Drug Administration, Drugs@FDA Database: Biologics License Application BLA 761085 (Jeuveau / Evolus ORIG Approval February 1, 2019): https://www.accessdata.fda.gov/scripts/cder/daf/
• PubMed Central / Dermatologic Surgery — Beer KR, et al. Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines in Adult Subjects: Results From 2 Identical Phase III Studies (EV-001 and EV-002). Dermatol Surg. 2019;45(11):1381-1393. PMC6819028: https://pmc.ncbi.nlm.nih.gov/articles/PMC6819028/
• PubMed Central / Aesthetic Surgery Journal — Fagien S, et al. An Open-Label and Double-Blind, Randomized, Active-Controlled Dose-Ranging Pilot Study to Evaluate the Efficacy and Safety of High-Dose PrabotulinumtoxinA in the Treatment of Moderate-to-Severe Glabellar Lines. Aesthet Surg J. 2024;44(9):987-1000. PMC11334208: https://pmc.ncbi.nlm.nih.gov/articles/PMC11334208/
• American Society for Dermatologic Surgery (ASDS) — Neuromodulator Aesthetic Practice Guidelines: https://www.asds.net/skin-experts/skin-treatments
• American Academy of Dermatology (AAD) — Botulinum Toxin Injection Safety and Dosing Overview: https://www.aad.org/public/cosmetic/wrinkles/botulinum-toxin-overview